4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
Last trade$10.63
Day change-$0.66 (-5.85%)
Day range$10.54 – $11.73
Volume422,882
Market cap$637M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$636.52M
Price / earnings
—
Price / book
1.56×
Price / sales
6.92×
EV / sales
6.37×
EV / EBITDA
-3.05×
Profitability
Earnings per share
-$3.18
Return on assets
-36.37%
Return on equity
-43.95%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.05×
Current ratio
8.03×
Quick ratio
8.03×
Cash ratio
1.48×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$156.18M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for FDMT, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$3.78M
$3.05M
$85.09M
$90K
$15K
$14K
$1K
$3K
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$3.78M
$3.05M
$85.09M
$90K
$15K
$14K
$1K
$3K
Selling, general and administrative
$12.52M
$11.69M
$12.77M
$11.84M
$11.52M
$12.94M
$13.03M
$12.65M
Research and development
$68.28M
$64.98M
$57.61M
$49.44M
$47.95M
$40.7M
$43.09M
$38.48M
Total operating expenses
$80.81M
$76.67M
$70.38M
$61.28M
$59.47M
$53.64M
$56.12M
$51.14M
Operating income
-$77.03M
-$73.62M
$14.72M
-$61.19M
-$59.46M
-$53.62M
-$56.12M
-$51.13M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$72.94M
-$68.76M
$19.4M
-$56.88M
-$54.66M
-$47.97M
-$49.67M
-$43.84M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$72.94M
-$68.76M
$19.4M
-$56.88M
-$54.66M
-$47.97M
-$49.67M
-$43.84M
Net income attributable to common shareholders
-$72.94M
-$68.76M
$19.4M
-$56.88M
-$54.66M
-$47.97M
-$49.67M
-$43.84M
EBITDA
-$75.75M
-$72.35M
$15.93M
-$59.92M
-$58.29M
-$52.57M
-$55.02M
-$49.94M
Basic earnings per share
-$1.04
-$1.01
$0.30
-$1.01
-$0.98
-$0.86
-$0.89
-$0.79
Diluted earnings per share
-$1.04
-$1.01
$0.30
-$1.01
-$0.98
-$0.86
-$0.89
-$0.79
Recent news
Company coverage with links to the original publishers.
4D Molecular Therapeutics reported a Q3 loss of $1.08 per share, missing EPS estimates by 3.85%, though it surpassed revenue expectations with $4.15 million (18.77% above consensus). The company showed significant year-over-year revenue growth from $0.09 million. The stock has gained 73.2% year-to-date, outperforming the S&P 500's 11.3% gain. The company received a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
MediWound (MDWD) reported a quarterly loss of $0.65 per share, slightly beating the consensus estimate of $0.66 loss, but significantly missed revenue expectations with $3.57 million versus the consensus estimate, representing a 53.15% miss. The company's stock has underperformed the market by 25.1% year-to-date. With a Zacks Rank #3 (Hold) rating and mixed estimate revisions, the stock is expected to perform in line with the market in the near term.
Journey Medical Corporation (DERM) is expected to report a quarterly loss of $0.03 per share for Q3 2026, representing a 66.7% improvement year-over-year, with revenues expected at $20.54 million, up 16.5%. However, the consensus EPS estimate has been revised 140% lower over the last 30 days, and the stock carries a Zacks Rank #4 with a negative Earnings ESP of -166.67%, making it unlikely to beat earnings expectations. The company has beaten consensus estimates only once in the last four quarters.
Stevanato Group (STVN) reported Q3 2026 earnings of $0.18 per share, beating consensus estimates of $0.17, with revenues of $375.28 million exceeding expectations by 3.14%. However, the stock has underperformed the S&P 500 by 12.1% year-to-date. The company received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. Meanwhile, peer company 4D Molecular Therapeutics is expected to report a quarterly loss of $1.04 per share.
4D Molecular Therapeutics (FDMT) is expected to report a quarterly loss of $1.04 per share with revenues of $3.49 million (up 3777.8% year-over-year) for Q3 2026. The company has a positive Earnings ESP of +4.35% combined with a Zacks Rank #3 (Hold), suggesting it will likely beat consensus EPS estimates. The stock has beaten estimates twice in the last four quarters.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.